{"id":391976,"date":"2020-12-02T11:53:39","date_gmt":"2020-12-02T16:53:39","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391976"},"modified":"2020-12-02T11:53:39","modified_gmt":"2020-12-02T16:53:39","slug":"quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/","title":{"rendered":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm"},"content":{"rendered":"
\n

\n Quantum Genomics to receive up to $<\/em>
\n 18.5<\/em>
\n million in upfront and milestone payments plus double-digit royalties on sales<\/em>
\n \n <\/p>\n

\n DongWha Pharm<\/em>
\n to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat\/resistant hypertension in <\/em>
\n South <\/em>
\n Korea<\/em>\n <\/p>\n

PARIS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Quantum\u00a0Genomics<\/strong>(Euronext\u00a0Growth – FR0011648971 – ALQGC)<\/strong>, a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat\/resistant hypertension, today announced it has entered into an exclusive licensing and collaboration agreement with DongWha Pharm to develop and commercialize firibastat in the Republic of Korea. After its last partnership in China, this new agreement is the third step of Quantum Genomics\u2019 partnering strategy in Asia.<\/p>\n

Under the terms of the agreement, DongWha will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat\/resistant hypertension in South Korea. Additionally, DongWha will join the global\u00a0 study of difficult to treat\/resistant hypertension in South Korea.<\/p>\n

Quantum Genomics will receive upfront and milestone payments amounting up to $18.5 million, plus double-digit royalties on sales.<\/p>\n

The population suffering from difficult to treat and resistant hypertension in the above territories is estimated to be about one million.<\/p>\n

\n \u201c<\/em>
\n Located in Seoul, DongWha Pharm is <\/em>
\n the<\/em>
\n perfect partner to launch firibastat in South Korea.<\/em>
\n For <\/em>
\n 120 years, DongWha Pharm has established various infrastructures including R&D, distribution and a strong sales organisation close to Key Opinion Leaders.<\/em>\n <\/p>\n

\n \u201cSince 1970, DongWha Pharm has achieved and maintained long-term partnerships with global pharmaceutical companies, among them <\/em>
\n Leo and Menarini<\/em>
\n .<\/em>\n <\/p>\n

\n \u201cWe are very much lookin<\/em>
\n g<\/em>
\n forward to working with DongWha Pharm on the clinical studies and then on the launch of firibastat<\/em>
\n ,\u201d <\/em>mentioned Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics.<\/p>\n

\n \u201c<\/em>
\n We are <\/em>
\n pleased <\/em>
\n to sign an exclusive contract for Firibastat <\/em>
\n of <\/em>
\n Quantum Genomics. Firibastat is a new class of drug entity that will satisfy the unmet needs of patients with <\/em>
\n difficult-to-treat\/<\/em>
\n resistant hypertension or heart failure, and <\/em>
\n we<\/em>
\n believe that this partnership will increase <\/em>
\n our<\/em>
\n market share in<\/em>
\n the cardiovascular field<\/em>
\n . In addition, we will continue to expand our pipelines through <\/em>
\n the <\/em>
\n open innovation,\u201d<\/em>\u00a0mentioned Ki-Whan Park, President and CEO of DongWha Pharm.<\/p>\n

\n About <\/strong>
\n DongWha<\/strong>
\n Pharm<\/strong>\n <\/p>\n

Established as the first Korean pharmaceutical company in 1897, DongWha is the most representative pharmaceutical company with high brand power. DongWha is a full-fledge equipped pharmaceutical company with its R&D center, manufacturing facility and nationwide sales and marketing network. DongWha has developed reliable long-term partnerships with global companies such as Leo, Menarini, Pfizer and so on. Under the spirit of the establishment \u201cServing customers through making good medicines and operating with the resulting revenues\u201d, DongWha has dedicated to developing innovative drugs.<\/p>\n

\n About Quantum Genomics<\/strong>\n <\/p>\n

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Coll\u00e8ge de France (French National Institute of Health and Medical Research (INSERM)\/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).<\/p>\n

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).<\/p>\n

For more information, please visit www.quantum-genomics.com<\/a>, or follow us on Twitter<\/a> and LinkedIn<\/a><\/p>\n

\n Contact information <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n
\n Quantum Genomics<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Jean-Philippe Milon
CEO
jean-philippe.milon@quantum-genomics.com<\/a><\/td>\n		Beno\u00eet Gueugnon
CFO
benoit.gueugnon@quantum-genomics.com<\/a><\/u><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n So Bang (Europe) <\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Nathalie Boumendil
Financial Communications
+33 (0)6 85 82\u00a041 95 | nathalie@so-bang.fr<\/a><\/td>\n		Samuel Beaupain
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | samuel<\/a>@so-bang.fr<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n LifeSci (USA)<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Dan Ferry
Financial Communications
+1 (617) 430-7576 | Daniel@lifesciadvisors.com<\/a>\u00a0<\/td>\n		Mike Tattory
Media Relations and Scientific Communications
+1 (609) 802-6265 | mtattory@lifescicomms.com<\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Quantum Genomics to receive up to $ 18.5 million in upfront and milestone payments plus double-digit royalties on sales DongWha Pharm to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat\/resistant hypertension in South Korea PARIS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Quantum\u00a0Genomics(Euronext\u00a0Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat\/resistant hypertension, today announced it has entered into an exclusive licensing and collaboration agreement with DongWha Pharm to develop and commercialize firibastat in the Republic of Korea. After its last partnership in China, this new agreement is the third step of Quantum Genomics\u2019 partnering strategy in Asia. … <\/p>\n

Continue reading “Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391976","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nQuantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Quantum Genomics to receive up to $ 18.5 million in upfront and milestone payments plus double-digit royalties on sales DongWha Pharm to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat\/resistant hypertension in South Korea PARIS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Quantum\u00a0Genomics(Euronext\u00a0Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat\/resistant hypertension, today announced it has entered into an exclusive licensing and collaboration agreement with DongWha Pharm to develop and commercialize firibastat in the Republic of Korea. After its last partnership in China, this new agreement is the third step of Quantum Genomics\u2019 partnering strategy in Asia. … Continue reading "Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T16:53:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm\",\"datePublished\":\"2020-12-02T16:53:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/\"},\"wordCount\":696,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/\",\"name\":\"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==\",\"datePublished\":\"2020-12-02T16:53:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/","og_locale":"en_US","og_type":"article","og_title":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm - Market Newsdesk","og_description":"Quantum Genomics to receive up to $ 18.5 million in upfront and milestone payments plus double-digit royalties on sales DongWha Pharm to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat\/resistant hypertension in South Korea PARIS, Dec. 02, 2020 (GLOBE NEWSWIRE) — Quantum\u00a0Genomics(Euronext\u00a0Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat\/resistant hypertension, today announced it has entered into an exclusive licensing and collaboration agreement with DongWha Pharm to develop and commercialize firibastat in the Republic of Korea. After its last partnership in China, this new agreement is the third step of Quantum Genomics\u2019 partnering strategy in Asia. … Continue reading \"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T16:53:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm","datePublished":"2020-12-02T16:53:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/"},"wordCount":696,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/","name":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==","datePublished":"2020-12-02T16:53:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTY0MSMzODUzMTk1IzUwMDA2NDExMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quantum-genomics-enters-into-exclusive-licensing-and-collaboration-agreement-with-dongwha-pharm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391976"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391976\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}